Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

290
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
290
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

24
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
24
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

23
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
23
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

232
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
232
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

286
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
286
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

729
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
729

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oyster Mushroom Cultivation on Coffee Parchment and <i>Cenchrus fungigraminus</i>: A Comparison of Disinfection Methods.

Journal of fungi (Basel, Switzerland)·2026
Same author

5-Acetyl-N-(1H-pyrazol-5-yl)furan-2-carboxamide as a novel orally available urea transporter inhibitor with improved properties.

European journal of medicinal chemistry·2026
Same author

Baseline Tumor Proliferation and Ki-67 Are Associated With Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-Small Cell Lung Cancer.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same author

Xiao-Jie-An Capsule Attenuates Oestrogen- and Progestogen-Induced Mammary Gland Hyperplasia by Modulating Sex Hormone Levels and Reducing Inflammatory Response.

Basic & clinical pharmacology & toxicology·2026
Same author

Xylarols A-G, structurally diverse specialized metabolites from mangrove endophytic fungus Xylaria sp. AH-75 and their anti-colorectal cancer activities.

Phytochemistry·2026
Same author

Chinese guidelines for HER2-targeted therapy in gastric and gastroesophageal junction adenocarcinoma (2025 Edition).

Journal of hematology & oncology·2026

Related Experiment Video

Updated: Oct 12, 2025

Assessment of Hippocampal Dendritic Complexity in Aged Mice Using the Golgi-Cox Method
09:44

Assessment of Hippocampal Dendritic Complexity in Aged Mice Using the Golgi-Cox Method

Published on: June 22, 2017

15.3K

Ganoderic acid improves 5-fluorouracil-induced cognitive dysfunction in mice.

Abudumijiti Abulizi1, Jianhua Ran2, Yuwei Ye1

  • 1State Key Laboratory of Natural and Biomimetic Drugs, Department of Pharmacology, School of Basic Medical Sciences, Peking University, Beijing, 100191, China. leemin@bjmu.edu.cn.

Food & Function
|November 25, 2021
PubMed
Summary
This summary is machine-generated.

Ganoderic acid (GA) protects against 5-Fluorouracil (5-FU) induced cognitive deficits by preserving mitochondrial function and promoting neuronal survival. This suggests GA may be a valuable adjunctive therapy for chemotherapy-related cognitive impairment.

More Related Videos

The Effect of Anti-Fatigue Decoction on the Behaviors and Serological Indicators in a Central Fatigue Rat Model
05:38

The Effect of Anti-Fatigue Decoction on the Behaviors and Serological Indicators in a Central Fatigue Rat Model

Published on: April 12, 2024

401
Quantifying Cognitive Decrements Caused by Cranial Radiotherapy
10:10

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy

Published on: October 18, 2011

12.8K

Related Experiment Videos

Last Updated: Oct 12, 2025

Assessment of Hippocampal Dendritic Complexity in Aged Mice Using the Golgi-Cox Method
09:44

Assessment of Hippocampal Dendritic Complexity in Aged Mice Using the Golgi-Cox Method

Published on: June 22, 2017

15.3K
The Effect of Anti-Fatigue Decoction on the Behaviors and Serological Indicators in a Central Fatigue Rat Model
05:38

The Effect of Anti-Fatigue Decoction on the Behaviors and Serological Indicators in a Central Fatigue Rat Model

Published on: April 12, 2024

401
Quantifying Cognitive Decrements Caused by Cranial Radiotherapy
10:10

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy

Published on: October 18, 2011

12.8K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Oncology

Background:

  • 5-Fluorouracil (5-FU) is a widely used chemotherapy agent with known neurotoxic side effects, including cognitive deficits.
  • Ganoderic acid (GA), derived from Ganoderma lucidum, exhibits neuroprotective properties.
  • Chemotherapy-induced cognitive impairment (CICI) significantly impacts patients' quality of life.

Purpose of the Study:

  • To investigate the efficacy of ganoderic acid (GA) in mitigating 5-Fluorouracil (5-FU)-induced cognitive dysfunction.
  • To elucidate the underlying mechanisms of GA's neuroprotective effects against 5-FU neurotoxicity.
  • To evaluate GA's potential as an adjunctive therapy for CICI.

Main Methods:

  • Mice were treated with 5-FU to induce cognitive deficits.
  • Behavioral tests were conducted to assess spatial and non-spatial memory.
  • Hippocampal tissues were analyzed for neuronal damage, mitochondrial structure, and protein expression related to mitochondrial biogenesis, dynamics, and neuronal survival.

Main Results:

  • GA significantly ameliorated memory impairments in 5-FU-treated mice.
  • GA protected hippocampal neurons and improved mitochondrial structure and dynamics.
  • GA normalized the expression of key proteins involved in mitochondrial function and neuronal growth signaling pathways.

Conclusions:

  • Ganoderic acid (GA) effectively prevents 5-Fluorouracil (5-FU)-induced cognitive dysfunction in mice.
  • GA exerts its protective effects by mitigating mitochondrial damage and enhancing neuronal survival and growth.
  • GA shows promise as a therapeutic agent to manage chemotherapy-related cognitive impairment.